



IFW

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: GASCO ET AL-1 PCT
SERIAL NO.: 10/533,512
FILED: MAY 2, 2005
TITLE: PHARMACEUTICAL COMPOSITIONS SUITABLE FOR THE
TREATMENT OF OPHTHALMIC DISEASES

INFORMATION DISCLOSURE STATEMENT

MAIL STOP: AMENDMENT
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants wish to bring to the attention of the Patent Examiner the references listed on the enclosed Form PTO-1449 and attached thereto. These references were cited in the International Search Report (copy enclosed). The remaining references were discussed in the Specification on Pages 1 and 2. Because this application was filed after June 30, 2003, copies of the U.S. patents are not included in accordance with current Patent Office guidelines.

Since this Information Disclosure Statement (IDS) is being filed before the issuance of a first Office Action on the merits, it is believed that no fee is due. However, the Commissioner is hereby authorized to charge Deposit Account No. 03-2468 for any additional fees or credit any overpayment in connection with this IDS. It is respectfully requested that the foregoing IDS be

incorporated into the official file of the present patent application.

Respectfully submitted,
Maria Rosa GASCO ET AL




COLLARD & ROE, P.C.
1077 Northern Boulevard
Roslyn, New York 11576
(516) 365-9802
FJD:lgh

Allison C. Collard, Reg.No.22,532
Edward R. Freedman, Reg.No.26,048
Frederick J. Dorchak, Reg.No.29,298
Attorneys for Applicant

Enclosures: PTO-1449 form and 3 references

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 7, 2005.



Melissa Konko

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. : GASCO ET AL-1 PCT		SERIAL NO. 10/533,512	
<div style="display: flex; align-items: center; justify-content: center;"> <div style="text-align: center;"> <p>LIST OF REFERENCES CITED BY APPLICANT</p> <p>(Use several sheets if necessary)</p> </div> <div style="border: 2px solid black; border-radius: 50%; padding: 10px; text-align: center; margin: 0 10px;"> <p>OIPF</p> <p>OCT 13 2005</p> <p>PATENT & TRADEMARK OFFICE</p> </div> </div>				APPLICANT: Maria Rosa GASCO ET AL.			
				FILING DATE: May 2, 2005		GROUP:	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,622,932 A	9/1997	Amselem et al. (ISR)			
	AB	6,419,949 B1	7/2002	Gasco (ISR)			
	AC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AL	EP 0 437 368 A	7/1991	EUROPEAN (ISR)			
	AM	WO 99/39700A	8/1999	PCT (ISR)			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR		Gasco, M.R., "Solid lipid nanospheres form warm micro-emulsions", Pharmaceutical Technology Europe, vol. 9, no. 11, 1997, pages 52-58, XP009030038, page 53, column 1-2, page 56, column 3-page 57, column 1. (ISR) ENCLOSED				
	AS		Cavalli, Roberta et al., "Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin", International Journal of Pharmaceutics (Kidlington), vol. 238, no. 1-2, 15 May 2002 (2002-05-15), pages 241-245, XP002278435, ISSN: 0378-5173, figure 1; tables 1-3 (ISR) ENCL.				
	AT		Komatsu A. et al., "Application of lipid microsphere drug delivery system to steroidal ophthalmic preparation.", Japanese Journal of Ophthalmology, Japan, 1988, vol. 32, no. 1, 1988, pages 41-43, XP009020506, ISSN: 0021-5155, page 43; table 1 (ISR) ENCL.				
	AU		Khoobehi B. et al., Ophthalmology 1988 Jul, 95 (7):950-5) (Spec) (to follow)				
	AV		Martidis A. et al., Ophthalmology 2002, 195(5):920-7). (Spec) (to follow)				
	AW		Morley MG. et al Ophthalmology 1998, 105(10): 1317). (Spec) (to follow)				
EXAMINER				DATE CONSIDERED			
/Gigi Huang/				01/14/2009			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./